Natixis’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $92.8M | Sell |
100,947
-104,055
| -51% | -$105M | 0.33% | 41 |
|
|
2025
Q4 | $220M | Sell |
205,002
-39,336
| -16% | -$37.6M | 0.78% | 16 |
|
|
2025
Q3 | $186M | Buy |
244,338
+2,285
| +0.9% | +$1.7M | 0.86% | 17 |
|
|
2025
Q2 | $189M | Sell |
242,053
-86,468
| -26% | -$67.2M | 0.84% | 20 |
|
|
2025
Q1 | $267M | Buy |
328,521
+190,546
| +138% | +$159M | 1.45% | 13 |
|
|
2024
Q4 | $107M | Sell |
137,975
-94,028
| -41% | -$77.9M | 0.65% | 25 |
|
|
2024
Q3 | $206M | Buy |
232,003
+73,860
| +47% | +$66.4M | 1.16% | 17 |
|
|
2024
Q2 | $143M | Sell |
158,143
-63,373
| -29% | -$50.7M | 0.82% | 19 |
|
|
2024
Q1 | $172M | Buy |
221,516
+63,654
| +40% | +$45.3M | 0.9% | 19 |
|
|
2023
Q4 | $92M | Sell |
157,862
-62,656
| -28% | -$36.6M | 0.67% | 23 |
|
|
2023
Q3 | $118M | Sell |
220,518
-129,555
| -37% | -$66.8M | 0.91% | 14 |
|
|
2023
Q2 | $164M | Buy |
350,073
+298,949
| +585% | +$125M | 1.33% | 10 |
|
|
2023
Q1 | $17.6M | Sell |
51,124
-152,118
| -75% | -$51.3M | 0.16% | 128 |
|
|
2022
Q4 | $74.4M | Sell |
203,242
-137,565
| -40% | -$48.8M | 0.42% | 61 |
|
|
2022
Q3 | $110M | Buy |
340,807
+214,678
| +170% | +$68M | 0.52% | 30 |
|
|
2022
Q2 | $40.9M | Sell |
126,129
-151,354
| -55% | -$45.4M | 0.15% | 89 |
|
|
2022
Q1 | $79.5M | Buy |
277,483
+147,266
| +113% | +$37.9M | 0.28% | 74 |
|
|
2021
Q4 | $36M | Buy |
130,217
+53,289
| +69% | +$13.5M | 0.12% | 150 |
|
|
2021
Q3 | $17.8M | Sell |
76,928
-16,540
| -18% | -$4.08M | 0.06% | 255 |
|
|
2021
Q2 | $21.5M | Buy |
93,468
+70,469
| +306% | +$14.2M | 0.09% | 185 |
|
|
2021
Q1 | $4.3M | Sell |
22,999
-343,527
| -94% | -$67.2M | 0.01% | 544 |
|
|
2020
Q4 | $61.9M | Buy |
366,526
+137,953
| +60% | +$20.6M | 0.22% | 100 |
|
|
2020
Q3 | $33.8M | Buy |
228,573
+73,096
| +47% | +$11.3M | 0.25% | 102 |
|
|
2020
Q2 | $25.5M | Buy |
155,477
+139,396
| +867% | +$21.4M | 0.2% | 100 |
|
|
2020
Q1 | $2.23M | Sell |
16,081
-234,876
| -94% | -$32.3M | 0.02% | 373 |
|
|
2019
Q4 | $33M | Buy |
250,957
+172,026
| +218% | +$19.9M | 0.2% | 129 |
|
|
2019
Q3 | $8.83M | Buy |
+78,931
| New | +$8.79M | 0.06% | 279 |
|
|
2018
Q4 | – | Sell |
-360,151
| Closed | -$38.6M | – | 765 |
|
|
2018
Q3 | $38.6M | Buy |
360,151
+263,825
| +274% | +$26.4M | 0.22% | 107 |
|
|
2018
Q2 | $8.22M | Sell |
96,326
-70,318
| -42% | -$5.78M | 0.04% | 315 |
|
|
2018
Q1 | $12.9M | Buy |
166,644
+57,354
| +52% | +$4.62M | 0.08% | 225 |
|
|
2017
Q4 | $9.23M | Sell |
109,290
-268,822
| -71% | -$22.9M | 0.07% | 221 |
|
|
2017
Q3 | $32.3M | Sell |
378,112
-52,597
| -12% | -$4.31M | 0.3% | 85 |
|
|
2017
Q2 | $35.4M | Buy |
+430,709
| New | +$35.1M | 0.4% | 65 |
|
|
2017
Q1 | – | Sell |
-245,857
| Closed | -$18.1M | – | 993 |
|
|
2016
Q4 | $18.1M | Sell |
245,857
-225,277
| -48% | -$16.8M | 0.19% | 135 |
|
|
2016
Q3 | $37.8M | Buy |
471,134
+223,840
| +91% | +$17.9M | 0.44% | 67 |
|
|
2016
Q2 | $19.5M | Buy |
247,294
+85,291
| +53% | +$6.42M | 0.36% | 64 |
|
|
2016
Q1 | $11.7M | Buy |
+162,003
| New | +$12.3M | 0.2% | 90 |
|
|
2015
Q4 | – | Sell |
-20,802
| Closed | -$1.74M | – | 345 |
|
|
2015
Q3 | $1.74M | Buy |
+20,802
| New | +$1.76M | 0.04% | 137 |
|
|
2015
Q2 | – | Sell |
-193,791
| Closed | -$14.1M | – | 408 |
|
|
2015
Q1 | $14.1M | Buy |
+193,791
| New | +$13.8M | 0.19% | 79 |
|
|
2014
Q3 | – | Sell |
-207,375
| Closed | -$12.9M | – | 458 |
|
|
2014
Q2 | $12.9M | Sell |
207,375
-561,297
| -73% | -$33.5M | 0.16% | 123 |
|
|
2014
Q1 | $45.2M | Sell |
768,672
-494,415
| -39% | -$27.6M | 0.59% | 41 |
|
|
2013
Q4 | $64.4M | Sell |
1,263,087
-107,991
| -8% | -$5.41M | 0.55% | 37 |
|
|
2013
Q3 | $69M | Buy |
1,371,078
+156,373
| +13% | +$8.19M | 0.74% | 33 |
|
|
2013
Q2 | $59.7M | Buy |
+1,214,705
| New | +$66.1M | 0.85% | 28 |
|
Other funds holding LLY
VCM
VPM
Natixis's LLY Position: Q1 2026 in Review
Natixis reduced its Eli Lilly (LLY) stake by 51% in Q1 2026, selling an estimated $105M and leaving 100,947 shares worth $92.8M. The position accounts for 0.33% of the portfolio, ranked #41.
Natixis first reported a position in LLY in Q2 2013 and has held it in 44 quarters since. The position peaked at $267M in Q1 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Natixis held 100,947 shares of Eli Lilly worth $92.8M as of Q1 2026.
- Natixis sold 104,055 Eli Lilly shares in Q1 2026, an estimated $105M.
- Eli Lilly made up 0.33% of Natixis's portfolio in Q1 2026, its #41 holding.
- Natixis first reported a position in Eli Lilly in Q2 2013 and has held it in 44 quarters since.
- Natixis's Eli Lilly position peaked at $267M in Q1 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.